BMRN — BIOMARIN PHARMACEUTICAL INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1048477 ·
Last close
$60.26
Market Cap
$11.66B
52W High
$70.98
52W Low
$49.26
ADV30
1,885,333
Next earnings
2026-10-26
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 989,708,000 | 786,913,000 | 110,969,000 | 44,762,000 | 11,723,442,000 | 874,005,000 | 5,401,750,000 |
| Mar 2026 | 766,208,000 | 571,209,000 | 129,630,000 | 105,527,000 | 8,591,016,000 | 2,222,435,000 | 2,378,909,000 |
| Dec 2025 | 874,565,000 | 598,856,000 | -44,603,000 | -46,573,000 | 7,594,022,000 | 1,311,679,000 | 1,507,023,000 |
| Sep 2025 | 776,133,000 | 636,048,000 | -46,677,000 | -30,744,000 | 7,614,868,000 | 1,250,108,000 | 1,558,157,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$874,251,000
Investing CF
$339,524,000
Financing CF
$809,552,000
CapEx
$-115,130,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$1.37
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$304,495,000
Inventory
$1,782,524,000
Receivables
$1,061,047,000
ST Investments
$0
EBIT TTM
$232,720,000
Pretax Income TTM
$149,110,000
Interest Exp TTM
$83,610,000
Analysts
25
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,406,614,016
EBITDA
$645,318,976
Free Cash Flow
$85,157,376
Enterprise Value
$16,042,119,168
Total Cash
$874,004,992
Total Debt
$4,202,200,064
Shares Out
193,573,759
Trailing EPS
$0.37
Book Value
$32.66
ROE
1.2%
ROA
3.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,221,253,000 | 409,495,000 | 348,901,000 | 7,594,022,000 | 1,507,023,000 | 6,086,999,000 | 827,994,000 |
| Dec 2024 | 2,853,915,000 | 474,239,000 | 426,859,000 | 6,988,940,000 | 1,330,950,000 | 5,657,990,000 | 572,841,000 |
| Dec 2023 | 2,419,226,000 | 185,780,000 | 167,645,000 | 6,841,603,000 | 1,890,054,000 | 4,951,549,000 | 159,259,000 |
| Dec 2022 | 2,096,039,000 | 57,410,000 | 141,561,000 | 6,375,074,000 | 1,771,918,000 | 4,603,156,000 | 175,902,000 |
TTM Snapshot
Revenues TTM
$2,577,558,000
NetIncome TTM
$325,492,000
OpCashFlow TTM
$0
Assets (Latest)
$7,594,022,000
Forward EPS
$6.54
Max Pain — expiry 2026-10-16
max pain strike: $60.00 · spot: $59.45 · call oi: 5,259 · put oi: 2,933
Expected Move to 2026-10-16:
±$3.95
(6.64%) —
implied range
$55.50 –
$63.40
· ATM straddle on $60.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | $11.93B | $516.56 | — |
| ELAN | Elanco Animal Health Inc | $11.14B | $22.31 | — |
| SMMT | Summit Therapeutics Inc. | $12.45B | $15.61 | — |
| CORT | CORCEPT THERAPEUTICS INC | $12.55B | $116.10 | — |
| BBIO | BridgeBio Pharma, Inc. | $12.82B | $65.57 | — |
News headlines (Yahoo Finance, 1h cache)
3 Healthcare Stocks That Fall Short
2026-09-28 09:18 · Yahoo
What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)?
2026-09-19 14:12 · Yahoo
BioMarin Stops Voxzogo Development for Noonan Syndrome
2026-09-16 16:01 · Yahoo
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors
2026-09-14 13:05 · Yahoo
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis
2026-09-12 17:02 · Yahoo
BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence
2026-09-09 13:05 · Yahoo
Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC
2026-09-09 08:23 · Yahoo
BioMarin (BMRN) Secured 20% U.S. Royalties on Yuviwel. Is Monetizing a Rival Better than Blocking It?
2026-09-04 16:26 · Yahoo
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout
2026-09-04 07:24 · Yahoo
Avenzo Therapeutics Announces Appointment of Barbara Bodem and Elizabeth Mily to Board of Directors as Independent Directors
2026-09-03 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.